AliveCor pricing
No price is published for Kardia 12L, the clinical system the company leads with: no device, software, per study, subscription or volume terms, though a purchasing route for providers exists. The company reported Medicare payment approval for Kardia 12L in hospital outpatient settings in 2025, which is what Medicare pays the provider per study, not what a practice pays AliveCor.
How AliveCor pricing works
- Pricing model
- Kardia 12L price not published (provider purchasing route; Medicare outpatient payment approved in 2025); consumer devices sold at retail; KardiaACCESS at no out of pocket cost to eligible Medicare beneficiaries
- Implementation
- Not published; Medicare payment approved for hospital outpatient use in 2025
KardiaMobile personal ECG devices are retail products bought directly by consumers, a side line to the clinical system. In September 2026 the company launched KardiaACCESS under the CMS ACCESS Model, giving eligible Original Medicare beneficiaries connected devices and clinician guided care at no out of pocket cost; its terms for clinicians and payers are not published. Whether the interpretation software is licensed separately when used with other compatible devices is not stated.
AliveCor pricing against its alternatives
Published prices for AliveCor and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.
- AAliveCorKardia 12L pricing not published. Consumer devices sold at retail
- AAnumanaNo published price
- IiRhythm TechnologiesNo price published; reimbursed diagnostic service billed under procedure codes
- NNanowearNo published price
- BBiofourmisNo published price
- CCadenceNot recorded
- IImplicityNo pricing published; reimbursement basis cited for the AF module in France
- HHeartSciencesNo published price
- AAccurKardiaNo published price
AliveCor pricing, answered
How much does AliveCor cost?
No price is published for Kardia 12L, the clinical system the company leads with: no device, software, per study, subscription or volume terms, though a purchasing route for providers exists. The company reported Medicare payment approval for Kardia 12L in hospital outpatient settings in 2025, which is what Medicare pays the provider per study, not what a practice pays AliveCor.
Does AliveCor charge an implementation fee?
Not published; Medicare payment approved for hospital outpatient use in 2025